FLEX NEOADJUVANT PUBLICATIONS & ABSTRACTS

Clinical evidence from FLEX


Neoadjuvant publications

Evidence / Neoadjuvant / FLEX

Real-World Evidence From FLEX: Utility of MammaPrint in Guiding Treatment Planning for Patients Aged 70 and Older With Early-Stage Breast Cancer

Publication: ASCO® 2025 Authors: Reshma Mahtani, Ana Sandoval-Leon, Anna Schrieber, Cathy Graham, Lauren Carcas, Naomi Dempsey, Victoria Poillucci, Michelle Landon, Christa Dreezen, William Audeh Title: Real-world Evidence from FLEX: Utility of MammaPrint in guiding treatment planning for patients aged 70 and older with early-stage breast cancer Background: Older women Read More

Molecular Insights Into HR+/HER2+ Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint Genomic Subtypes

Publication: ASCO® 2025 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce O’Shaughnessy, William Audeh Title:Molecular Insights into HR+/HER2+Early-Stage Breast Cancer: Neoadjuvant Therapy Responses by MammaPrint and BluePrint genomic subtypes Background: Clinical HER2+ (cHER2+) early breast cancer (EBC) represents 15-20% of invasive EBC and is typically Read More

Association of ImPrintTN Signature With Survival Outcomes by Race in Basal-Type Triple Negative Breast Cancer

Publication: ASCO® 2025 Authors: Priyanka Sharma, Shane R. Stecklein, Denise M. Wolf, Christina Yau, Laura Esserman, Laura van t Veer, David B. Page, Harshini Ramaswamy, Sahra Uygun, Josien Haan, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O'Shaughnessy Title: Association of ImPrintTN signature with survival outcomes by race in Basal-Type Read More

The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis

Publication: ESMO Breast Cancer 2025 Authors: Brufsky, et al. Title: The impact of the 80-gene signature on pCR and chemotherapy treatment decisions in early-stage breast cancer: A FLEX analysis Background: The BluePrint (BP), 80-gene signature, provides insight into the intrinsic subtype of early-stage breast cancer (EBC). This study evaluates Read More

Real World Evidence of MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant setting

Publication: ASBRS 2025 Authors: Thompson et al. Title: Real World Evidence of MammaPrint® and BluePrint® utility for informing axillary surgery decisions in the neoadjuvant setting Introduction: Decisions regarding the extent of axillary surgery in HR+HER2- early-stage breast cancer (EBC) are primarily based on clinical factors, including age, T-stage, and Read More

Neoadjuvant HER2-Targeted Therapy Response by BluePrint Gene Expression-Based Molecular Subtyping in Patients with HER2+ Early-Stage Breast Cancer from FLEX

Publication: 19th SGBCC 2025-P201 Authors: Laila Samiian, Adam Brufsky, Sahra Uygun, Isha Kapoor, Victoria Poillucci, Joyce O’Shaughnessy, William Audeh Title: Neoadjuvant HER2-Targeted Therapy Response by BluePrint® Gene Expression-Based Molecular Subtyping in patients with HER2+ Early-Stage Breast Cancer from FLEX Introduction: • Clinical HER2+ (cHER2+) early-stage breast cancer (EBC) accounts Read More

Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King

Publication: International Journal of Molecular Sciences 2025, 26, 491 Authors: Rakhshanda Layeequr Rahman, Alfredo Santillan, Mehran Habibi, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Chmielewski-Stivers, Andrea Menicucci, William Audeh, and Joyce O’Shaughnessy Title: Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King Abtract: Clinical Read More